CLNN News and Press, Clene Inc. From 05/08/24

2024-05-08 09:54:58 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene GAAP EPS of -$0.09

Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8 ® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) Peer-reviewed publication characterized the protein co...

Researchers from The Ohio State University have found that disturbed neuronal activity may cause metabolism issues in individuals who suffer spinal-cord injuries. Findings from an animal study suggest that heart attacks, diabetes and vascular conditions that typically affect patients postspin...

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Rob Ethe...

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily ...

LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) --  via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceu...

CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance funct...

2024-04-17 17:30:02 ET Benchmark analyst issues UNDERPERFORM recommendation for CLNN on April 17, 2024 04:02PM ET. The previous analyst recommendation was Underperform. CLNN was trading at $0.3396 at issue of the analyst recommendation. The overall analyst consensus : BU...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (ȁ...

2024-04-17 06:55:40 ET DENVER, Colo., Apr 17, 2024 ( 247marketnews.com )- Clene Inc. (Nasdaq: CLNN ) presented Phase 2 VISIONARY-MS long term extension (LTE) study results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver. The improved clinical, functional, an...